Role of Infectious Diseases Consultants in Management of Antimicrobial Use in Hospitals
|
|
- Geraldine Robinson
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Role of Infectious Diseases Consultants in Management of Antimicrobial Use in Hospitals Rebecca H. Sunenshine, 1 Laura A. Liedtke, 3 Daniel B. Jernigan, 5 and Larry J. Strausbaugh, 1,2,3,4 for the Infectious Diseases Society of America Emerging Infections Network 1 Division of Infectious Diseases, Department of Medicine, and 2 School of Medicine, Oregon Health & Science University, and 3 Research Service and 4 Infectious Disease Section, Division of Hospital and Specialty Medicine, Veterans Affairs Medical Center, Portland, Oregon; and 5 Office of Surveillance, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia (See the editorial commentary by McGowan on pages ) The Infectious Diseases Society of America Emerging Infections Network (EIN) surveyed its members to characterize antimicrobial restriction policies in their hospitals and the involvement of infectious diseases consultants in this process. Of the 502 respondents (73%), 250 (50%) indicated that their hospital pharmacies would not dispense certain antimicrobials without approval of infectious diseases consultants. Moreover, 89% agreed that infectious diseases consultants need to be directly involved in the approval process. At hospitals with control policies, commonly restricted agents included lipid formulations of amphotericin B, carbapenems, fluoroquinolones, piperacillin-tazobactam, and vancomycin. Only 46 EIN members (18%) reported remuneration of infectious diseases consultants for participation in the approval process. Pediatric infectious diseases consultants were more likely to practice in hospitals with restriction policies than were adult infectious diseases consultants (64% vs. 45%; P!.001). Similarly, teaching hospitals were more likely to have antimicrobialcontrol policies than were nonteaching facilities (60% vs. 17%; P!.001). In some hospitals, the pharmacy will not dispense certain antimicrobial agents without the approval of a physician trained in infectious diseases. This practice reduces both the use and the costs of these agents [1 3]. In several studies, this practice and other methods used to restrict antimicrobial use have decreased the incidence of certain drug-resistant organisms in health care Received 20 August 2003; accepted 6 November 2003; electronically published 15 March Presented in part: 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania, November 1999 (abstract 601). Published as abstract 585 in Clin Infect Dis 1999; 29:1064. Financial support: Centers for Disease Control and Prevention (cooperative agreement U50/CCU112346). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. Reprints or correspondence: Dr. Larry J. Strausbaugh, Div. of Hospital and Specialty Medicine (P3-ID), Veterans Affairs Medical Center, PO Box 1034, Portland, OR (strausba@ohsu.edu). Clinical Infectious Diseases 2004; 38: by the Infectious Diseases Society of America. All rights reserved /2004/ $15.00 settings [2, 4 6]. Despite these observations, it is not known how many hospitals require approval by infectious diseases consultants for the release of certain antimicrobial agents. Accordingly, the Infectious Diseases Society of America (IDSA) Emerging Infections Network (EIN) surveyed its membership about approval policies in their hospitals. The survey also solicited attitudes and information about the approval processes and related issues, such as drug targets and reimbursement for participation. METHODS The IDSA EIN is a provider-based sentinel network that was established in 1995 through a Cooperative Agreement Program award from the Centers for Disease Control and Prevention (CDC) to the IDSA [7]. It comprises volunteers who belong to either the IDSA or the Pediatric Infectious Diseases Society (PIDS) and practice adult and/or pediatric infectious diseases in the United States and other countries. Because 198% of 934 CID 2004:38 (1 April) Sunenshine et al.
2 EIN members practice in the United States, only information from these respondents was used in this analysis. During March 1999, the IDSA EIN distributed a 2-page introduction and a 1-page questionnaire via facsimile to all 690 EIN members. Members who did not respond received a second facsimile and reminder 2 weeks after the original query was sent. The survey inquired about members attitudes regarding the relationship between antimicrobial resistance and use, the role of infectious diseases consultants in hospital approval processes, and the likelihood of antagonizing other colleagues by involving infectious diseases consultants in the approval process. It also asked about the use of such approval processes in their primary inpatient workplaces. Members who worked in hospitals requiring infectious diseases approval for certain agents were asked about remuneration and drugs targeted for approval. Members who did not work in hospitals requiring infectious diseases approval for release of any antibiotic were questioned about their support for an approval process, their willingness to participate, and ideal agents to restrict. Responses from members practicing in university and nonuniversity teaching hospitals were similar; accordingly, the data were combined and compared with responses from members practicing in nonteaching hospitals. x 2 Analysis was used to test differences in frequencies for statistical significance. RESULTS Characteristics of respondents. Overall, 502 (73%) of the 690 surveyed EIN members responded. Of these respondents, 116 (23%) indicated that they work with pediatric patients exclusively, and 341 (68%) indicated that they work with adult patients exclusively (table 1). Response rates were similar for both groups. In addition, 197 respondents (39%) described their principal inpatient setting as a university teaching hospital, 187 (37%) described it as a nonuniversity teaching hospital, Table 1. Number of Emerging Infections Network member hospitals requiring approval by an infectious diseases consultant to dispense certain antimicrobial agents. Type of hospital Pediatric patients Type of infectious diseases practice Adult patients 109 (22%) described it as a nonteaching hospital, and 9 (2%) did not specify the nature of their primary inpatient workplace. General perspective of respondents. Of the 502 respondents, 467 (93%) agreed that inappropriate use of antimicrobial agents is the most important factor contributing to the burgeoning problem of antimicrobial resistance in US hospitals. Approximately the same percentage of pediatric (96%) and adult (93%) infectious diseases consultants agreed with this statement. Furthermore, 447 (89%) of the respondents agreed that infectious diseases consultants need to be directly involved in the approval process for use of selected antimicrobial agents prescribed for individual patients in their hospital settings. However, 224 (45%) judged that infectious diseases consultants participation in the approval process would antagonize colleagues in other specialties and would possibly lead to a loss of income from decreased requests for consultation. Of interest, 57% of infectious diseases consultants who practiced in nonteaching facilities agreed that the approval process would antagonize colleagues, compared with 42% of respondents who practiced in teaching facilities ( P p.007). In addition, 135 (60%) of 224 respondents concerned about negative ramifications of the approval process practice in institutions where approval is not required. Practice in respondent hospitals. Of the 502 respondents, 250 (50%) reported that approval by infectious diseases consultants is required for their pharmacy to dispense certain antimicrobial agents in their primary inpatient workplace (table 1). The frequency of hospitals requiring approval, as reported by EIN members, varied somewhat by hospital setting, type of practice, and region. For example, 232 (60%) of 384 members practicing in teaching facilities reported that infectious diseases approval is required for certain antimicrobial agents, whereas only 18 (17%) of 109 respondents in nonteaching hospitals reported requirements for infectious diseases approval (P!.001). Both adult and pediatric patients Unspecified Total Teaching 74/ /241 18/25 2/5 232/384 University 55/78 75/104 8/12 1/3 139/197 Nonuniversity 19/35 63/137 10/13 1/2 93/187 Nonteaching 0/2 16/94 2/12 0/1 18/109 Unspecified 0/1 0/6 0/1 0/1 0/9 Total 74/ /341 20/38 2/7 250/502 NOTE. Data are no. of respondents who reported that their hospital required approval by an infectious diseases consultant to dispense certain antimicrobial agents/no. of respondents. Management of Antimicrobial Use CID 2004:38 (1 April) 935
3 In terms of practice type, 74 (64%) of 116 pediatric infectious diseases consultants and 154 (45%) of 341 adult infectious diseases consultants reported requirements for infectious diseases approval in their hospitals ( P!.001). In addition, 68% of EIN members practicing in the New England and mid- Atlantic regions worked in hospitals that required approval by infectious diseases consultants for release of some antimicrobial agents. In the other 7 regions of the United States delineated by the CDC, the percentage of respondents working in hospitals that require approval ranged from 23% in the West North Central region to 55% in the Mountain region. Of the 252 EIN respondents practicing in hospitals without infectious diseases approval processes, 145 (58%) thought that their facility should adopt such policies and indicated willingness to participate for some portion of the year. When stratified by practice type, 102 (55%) of 187 adult medicine practitioners, 29 (69%) of 42 pediatric medicine practitioners, and 12 (67%) of 18 members who practice with both populations agreed with the adoption of such a policy and would be willing to participate. Similarly, in this subgroup, 87 (57%) of 152 members in teaching hospitals and 54 (59%) of 91 members in nonteaching hospitals favored approval programs. Target antimicrobial agents for restriction by approval policies. Of the 250 infectious diseases consultants who practice in hospitals with approval processes, agents targeted include: lipid formulations of amphotericin B, carbapenems, fluoroquinolones, piperacillin/tazobactam, and vancomycin (table 2). Respondents working in institutions without infectious diseases approval policies identified a similar range of antimicrobial agents for potential restriction (table 2). Remuneration. Only 46 (18%) of 250 EIN respondents who work in hospitals with restriction policies reported that infectious diseases consultants receive direct remuneration for their participation. Of these 46 respondents, 8 engage in pediatric practice and 32 engage in adult practice. Of interest, 40 (17%) of 232 respondents practicing in teaching facilities and 6 (33%) of 18 respondents practicing in nonteaching facilities report compensation of infectious diseases consultants for their role in the restriction process. Remuneration derived from general hospital funds for 24 of these members and from pharmacy savings for 6 other members. The remaining 16 members did not specify the source of their remuneration. Several respondents reported indirect benefits, such as funding for fellowship positions, increased consultation requests, and leverage in salary negotiations. DISCUSSION Table 2. Antimicrobials targeted for control in Emerging Infections Network (EIN) hospitals with and EIN hospitals without antibiotic approval processes. Antimicrobial agent or class No. of EIN members Hospital requires approval to dispense agent (n p 250) Hospital does not require approval to dispense agent a (n p 252) Lipid formulations of amphotericin B Carbapenems Fluoroquinolones Piperacillin-tazobactam Vancomycin Other 103 b 67 c a EIN members in hospitals without approval processes were asked which antimicrobial agents should require approval by an infectious diseases consultant. b Includes cephalosporins ( n p 42; predominantly third-generation cepha- losporins and cefepime), aminoglycosides ( n p 19), fluconazole ( n p 19), az- treonam ( n p 15), antivirals ( n p 11), other b-lactams ( n p 9), quinupristin- dalfopristin ( n p 3), azithromycin ( n p 3), intravenous immunoglobulin ( n p 3), and antiretrovirals ( n p 3). c Includes cephalosporins ( n p 10), other antifungals ( n p 10), quinupristin- dalfopristin ( n p 8), and antivirals ( n p 4). Almost all respondents agreed that inappropriate use of antibiotics is the most important factor contributing to increased antibiotic resistance. This opinion undoubtedly reflects a growing body of literature that demonstrates a relationship between antimicrobial use and resistance [8 13]. For example, Seppälä et al. [14] and Arason et al. [15] have demonstrated that reduced antimicrobial use can lead to a decrease in the frequency of antimicrobial-resistant organisms. In these 2 large community-based studies done in Iceland and Finland, respectively, decreased use of penicillin and erythromycin resulted in marked reductions of the rates of penicillin-resistant pneumococci and erythromycin-resistant Streptococcus pyogenes. Similarly, when White et al. [16] instituted a restrictive antibiotic policy in their hospital, the frequency of multidrug-resistant Acinetobacter species decreased significantly. Nearly all respondents agreed that infectious diseases consultants should be directly involved in the approval process of selected antimicrobial agents. This judgment may derive from their perception that physicians overuse antimicrobial agents. Numerous studies have demonstrated that these drugs are often used inappropriately and excessively. For example, Murthy [17] found that 25% 50% of antibiotic prescriptions were inappropriate because incorrect choices were made with regard to drug, dose, or duration. Moreover, policies that reduce the use of certain antibiotics effectively diminish the frequency of antibiotic-resistant organisms. In his review of the literature, Gould [5] provided a rationale for antibiotic restriction programs aimed at reducing overuse of antibiotics demonstrating that they often prove to be effective in decreasing drug-resistant organisms. Accordingly, efforts to improve antimicrobial use 936 CID 2004:38 (1 April) Sunenshine et al.
4 practices have considerable appeal to those interested in combating antimicrobial resistance [18]. Gómez et al. [19] have emphasized the clinical value of combining microbiologic information with the input of infectious diseases consultants. In their study, this combination yielded not only more appropriate empirical and directed therapy but also improved clinical outcomes. Likewise, in their review of the literature, John and Fishman [3] found ample evidence that interventions by infectious diseases consultants improve use and reduce costs of antimicrobial agents. Furthermore, Sáez- Llorens et al. [20] described similar findings in Panama when an antibiotic restriction policy involving infectious diseases consultants led to significant reductions in antimicrobial use, costs, and resistance patterns. The improved use observed in these studies suggests that involvement of infectious diseases consultants in the selection of antimicrobial agents will lead to decreased resistance. Our survey examined the role that infectious diseases consultants play in this effort to improve or restrict antimicrobial use. The percentage of respondents whose hospitals utilize infectious diseases consultants in an approval process ranged from 17% in nonteaching hospitals, to 50% in nonuniversity teaching hospitals, to 71% in university teaching hospitals. These latter percentages approximate the figure reported by Klapp and Ramphall [21] in their 1983 summary of 108 teaching hospitals. The higher percentages for university teaching hospitals may reflect participation of infectious diseases fellows in the approval process. Notwithstanding, 29% of respondents in university teaching hospitals report a lack of approval programs involving infectious diseases staff. Why are approval processes involving infectious diseases consultants underused? One impediment may be the time and effort required to maintain such an approval program. For example, Woodward et al. [1] found that their program required 24 h per month of an infectious diseases fellow s time, 76 h per month from the pharmacy, and 10 h per month combined from the infectious diseases faculty. At institutions without fellows, this load would fall on hospital staff members who would not likely undertake this responsibility without appropriate compensation. The lack of compensation, therefore, is a second noteworthy barrier to participation by infectious diseases consultants in hospital approval programs. In our survey, only 18% of respondents received direct remuneration for their efforts. They indicated that their compensation derived from general hospital funds or pharmacy savings. Although numerous studies have demonstrated significant cost savings achieved through restriction programs [1, 3], it appears that few hospitals have acted on this finding. Hospital administrators may hesitate to remunerate infectious diseases consultants for their antibiotic management activities without either guarantees or estimates of pharmacy savings. The results of our survey suggest a third barrier: the possible collegial downside to restricting choice of specific antimicrobials. On the basis of our study, it appears that infectious diseases consultants fear that their role in the approval process will antagonize colleagues in other specialties. It is difficult to estimate the validity of this concern. In their study involving several teaching institutions, Woodward et al. [1] detected no increase in inappropriate prescription of antimicrobials to avoid contact with the infectious diseases service. In fact, the requests for use of restricted or controlled antibiotics frequently developed into useful teaching sessions about actual clinical problems [1, p. 822]. Several EIN members also remarked on this aspect of approval programs. Whether this finding would hold true in a nonteaching setting is unknown. Despite these barriers to use of infectious diseases consultants in approval processes, there is considerable consensus about which drugs to target. In general, EIN respondents agreed that the ideal antimicrobials to target for restriction are newer broad-spectrum agents, such as carbapenems, fluoroquinolones, and piperacillin-tazobactam, and the newer antifungals. These targets are similar to ones identified by several authors who have emphasized the need to control newer, more expensive, broad-spectrum agents with activity worth conserving [4, 5]. The EIN members who do not currently participate in an approval program proposed the same antibiotic classes as targets for restriction. Of note, this survey was distributed before the release of linezolid. With the emergence of vancomycinresistant Staphylococcus aureus [22], one can speculate that most infectious diseases consultants would add this drug to their approval list, hoping to prolong its utility. We acknowledge several limitations in our survey data. EIN members, who are volunteers from the IDSA and PIDS, may not be a representative sample of infectious diseases consultants in the United States. Nevertheless, the respondents to this survey practiced in 49 of 50 states and served in a variety of hospital settings. It is possible that survey data include responses from 11 individual practicing in the same inpatient facility. This seems unlikely, because many EIN members have indicated that a designated individual responds for their group. It is also possible that antimicrobial management practices have changed since this survey was issued in March This, too, seems unlikely for several reasons (e.g., continued cost cutting in health care facilities, contraction of inpatient services, absence of a national initiative to establish restriction programs, and absence of data from controlled studies to validate utility of this approach). Finally, this study does not include information about logistical details that make restriction programs work, such as fellow involvement in university hospitals. We hope to Management of Antimicrobial Use CID 2004:38 (1 April) 937
5 address these issues and outcomes of restriction programs in a future EIN survey. In summary, most infectious diseases consultants who responded to our survey favor policies that make use of certain antimicrobial agents contingent upon approval by infectious diseases consultants; however, only one-half practice in hospitals that have such policies, and few receive direct remuneration for their efforts. Such policies are used less commonly in nonteaching hospitals and also outside the Northeast and mid- Atlantic regions. Expanding the use of this practice to combat antimicrobial resistance will require efforts both to enhance incentives for infectious diseases consultants and to introduce this practice into nonteaching hospitals. Acknowledgments We thank Melissa Plantenga and Tia Neely for their assistance with data analysis and manuscript preparation. References 1. Woodward RS, Medoff G, Smith MD, Gray JL III. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school affiliated hospital. Am J Med 1987; 83: Frank MO, Batteiger BE, Sorensen SJ, et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997; 5: John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24: McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15: Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: Executive Committee of the Infectious Diseases Society of America Emerging Infections Network. The Emerging Infections Network: a new venture for the Infectious Diseases Society of America. Clin Infect Dis 1997; 25: Cordero L, Sananes M, Ayers LW. Bloodstream infections in a neonatal intensive-care unit: 12 years experience with an antibiotic control program. Infect Control Hosp Epidemiol 1999; 20: Schlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: Rice LB, Eckstein EC, DeVente J, Schlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996; 275: McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273: McGowen, JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycinresistance in group A Streptococci in Finland. N Engl J Med 1997; 337: Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 1996; 313: White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25: Murthy R. Implementation of strategies to control antimicrobial resistance. Chest 2001; 119:405S 11S. 18. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drugresistant Streptococcus pneumoniae (DRSP). JAMA 1996; 275: Gómez J, Conde Cavero SJ, Hernández Cardona JL, et al. The influence of the opinion of an infectious disease consultant on the appropriateness of antibiotic treatment in a general hospital. J Antimicrob Chemother 1996; 38: Sáez-Llorens X, Castrejón De Wong MM, Castaño E, De Suman O, De Morös D, De Atencio I. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J 2000; 19: Klapp DL, Ramphal R. Antibiotic restriction in hospitals associated with medical schools. Am J Hosp Pharm 1983; 40: Chang S, Sievert DM, Hageman JC, et al. Brief report: infection with vancomycin-resistant Staphylococcus aureus containing the vana resistance gene. N Engl J Med 2003; 348: CID 2004:38 (1 April) Sunenshine et al.
Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationAntimicrobial Stewardship Strategy: Formulary restriction
Antimicrobial Stewardship Strategy: Formulary restriction Restricted dispensing of targeted antimicrobials on the hospital s formulary, according to approved criteria. The use of restricted antimicrobials
More informationAntimicrobial Stewardship Program: Local Experience
Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH
More informationPreventing and Responding to Antibiotic Resistant Infections in New Hampshire
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationImpact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study
Int J Clin harm (2012) 34:290 294 DOI 10.1007/s11096-012-9621-7 SHORT RESEARCH REORT Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies
ASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies Theresa Jaso, PharmD, BCPS (AQ-ID) Network Clinical Pharmacy Specialist Infectious Diseases Seton Healthcare Family Ascension
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationObjective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest
Expanding Antimicrobial Stewardship into the Outpatient Setting Michael E. Klepser, Pharm.D., FCCP Professor Pharmacy Practice Ferris State University College of Pharmacy Disclosure Statement of Financial
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationImplementing Antibiotic Stewardship in Rural and Critical Access Hospitals
National Center for Emerging and Zoonotic Infectious Diseases Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals Denise Cardo, MD Director, Division of Healthcare Quality Promotion,
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION A Survey of Knowledge, Attitudes, and Beliefs of House Staff Physicians From Various Specialties Concerning Antimicrobial Use and Resistance Arjun Srinivasan, MD; Xiaoyan Song, MD;
More informationThis survey was sent only to EIN members with a pediatric infectious diseases practice.
Infectious Diseases Society of America Emerging Infections Network Report for Query: Pediatric Outpatient Parenteral Antibiotic Therapy (OPAT) Overall response rate: 188/281 (66.9%) physicians responded
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationThe UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England
The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England Chief Medical Officer - Annual Report 2013 Antimicrobial resistance poses catastrophic
More informationAntimicrobial Stewardship Strategy: Intravenous to oral conversion
Antimicrobial Stewardship Strategy: Intravenous to oral conversion Promoting the use of oral antimicrobial agents instead of intravenous administration when clinically indicated. Description This is an
More informationBugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care
Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care Molly Curran, PharmD, BCPS Clinical Assistant Professor The University of Texas College of Pharmacy Clinical
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationCommonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities
Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we
More informationIt s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP
It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings Emily Heil, PharmD, BCPS-AQ ID, AAHIVP Conflict of Interest I have no conflicts of interest to disclose related to the content
More information2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea
2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea Submitted by: Asia Pacific Foundation for Infectious Diseases Policy Forum on Strengthening Surveillance and Laboratory Capacity to
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationMDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC
MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:
More informationANTIBIOTIC STEWARDSHIP
ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More informationCompliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings
Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntimicrobial Stewardship Strategy:
Antimicrobial Stewardship Strategy: Prospective audit with intervention and feedback Formal assessment of antimicrobial therapy by trained individuals, who make recommendations to the prescribing service
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationStudies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India
Human Journals Research Article April 2016 Vol.:6, Issue:1 All rights are reserved by Zarine Khety et al. Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Keywords: Drug
More informationExecutive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts
Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts Investigational Team: Diane Brideau-Laughlin BSc(Pharm),
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationOutpatient Antimicrobial Stewardship. Jeffrey S Gerber, MD, PhD Division of Infectious Diseases The Children s Hospital of Philadelphia
Outpatient Antimicrobial Stewardship Jeffrey S Gerber, MD, PhD Division of Infectious Diseases The Children s Hospital of Philadelphia Overview The case for outpatient antimicrobial stewardship Interventions
More informationWhat is the problem? Latest data on antibiotic resistance
European Antibiotic Awareness Day 2009 What is the problem? Latest data on antibiotic resistance Zsuzsanna Jakab, ECDC Director Launch Seminar for EAAD Stockholm, 18 November 2009 Fluoroquinolone-resistant
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationThe World Health Organization has referred to. Antibiotic Resistance: The Iowa Experience DRUG UTILIZATION. Nancy Bell, RPh
DRUG UTILIZATION Antibiotic Resistance: The Iowa Experience Nancy Bell, RPh Background: In the past 10 years, the number of strains of Streptococcus pneumoniae and other common respiratory pathogens that
More informationAn Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?
An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? Dr. Andrew Morris Antimicrobial Stewardship ProgramMt. Sinai Hospital University Health Network amorris@mtsinai.on.ca andrew.morris@uhn.ca
More informationIncidence of hospital-acquired Clostridium difficile infection in patients at risk
Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationA Nationwide Survey of Antimicrobial Stewardship Practices
Clinical Therapeutics/Volume 35, Number 6, 2013 Antimicrobial Stewardship A Nationwide Survey of Antimicrobial Stewardship Practices Shira Doron, MD 1 ; Lauren Nadkarni, BS 2 ; Lori Lyn Price, MAS 3 ;
More informationStreptococcus pneumoniae Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance
MAJOR ARTICLE Streptococcus pneumoniae Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance Jörg J. Ruhe and Rodrigo Hasbun Department of Medicine, Infectious Diseases
More informationAntimicrobial Prescribing for Upper Respiratory Infections and Its Effect on Return Visits
182 March 2009 Family Medicine Clinical Research and Methods Antimicrobial Prescribing for Upper Respiratory Infections and Its Effect on Return Visits John Li, MPH; Anindya De, PhD; Kathy Ketchum, RPh,
More informationAntibiotic stewardship in North Carolina hospitals
Introduction Antibiotic stewardship in North Carolina hospitals Ralph Raasch a, Laini Jarrett-Echols b, Carol Koeble c, Christine Pittman d The benefits of hospital-based antibiotic stewardship programs
More informationAntibiotic Stewardship and Critical Access Hospitals. Robert White, BA, PT, CPHQ Program Manager TMF Quality Innovation Network
Antibiotic Stewardship and Critical Access Hospitals Robert White, BA, PT, CPHQ Program Manager TMF Quality Innovation Network Antibiotic-Resistant Bacteria A serious threat to public health and the economy
More informationAntibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE
Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org
More informationGeriatric Mental Health Partnership
Geriatric Mental Health Partnership September 8, 2017 First, let s test your knowledge about antibiotics http://www.cdc.gov/getsmart/community/about/quiz.html 2 Get Smart Antibiotics Quiz Antibiotics fight
More informationPotential Conflicts of Interest. Schematic. Reporting AST. Clinically-Oriented AST Reporting & Antimicrobial Stewardship
Potential Conflicts of Interest Clinically-Oriented AST Reporting & Antimicrobial Stewardship Hsu Li Yang 27 th September 2013 Research Funding: Pfizer Singapore AstraZeneca Janssen-Cilag Merck, Sharpe
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationMHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative
MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative Place picture here Nov. 14, 2017 Reminders For best sound quality, dial in at 1-800-791-2345 and enter code 11076 Please use the chat box to ask questions!
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationGUIDELINES EXECUTIVE SUMMARY
GUIDELINES Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship Timothy
More informationAntimicrobial consumption
Antimicrobial consumption Annual Epidemiological Report for 2017 Key facts Twenty-seven countries, comprising 25 EU Member States and two EEA countries (Iceland and Norway) reported data on antimicrobial
More informationChallenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.
Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial
More informationGUIDELINES EXECUTIVE SUMMARY
GUIDELINES Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship Timothy
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationHospital - Leaders establish antimicrobial stewardship as an
Below please find the IDSA response to the Joint Commission s Proposed Standard for Antimicrobial Stewardship in various types of facilities, (AHC, CAH,HAP, NCC, and OBS). Comments are broken out by the
More informationWhy Antimicrobial Stewardship?
Antimicrobial Stewardship: Why and How CAPT Arjun Srinivasan, MD Associate Director for Healthcare Associated Infection Prevention Programs Division of Healthcare Quality Promotion Why Antimicrobial Stewardship?
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationEVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK
EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK EPIDEMIOLOGY AND BACKGROUND Every year, more than 2 million people in the United States acquire antibiotic-resistant
More informationUpdate on CDC Antibiotic Stewardship Activities
National Center for Emerging and Zoonotic Infectious Diseases Update on CDC Antibiotic Stewardship Activities CAPT Lauri Hicks, DO CAPT Arjun Srinivasan, MD Division of Healthcare Quality Promotion National
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationResponsible use of antibiotics
Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union November 2012 Highlights on antibiotic consumption Antibiotic use is one of the main factors responsible for the development and
More informationAntibiotic Stewardship in the Hospital Setting
Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationReady to Launch: Antimicrobial Stewardship for All!
Ready to Launch: Antimicrobial Stewardship for All! Lucas Schulz, PharmD, BCPS AQ ID Clinical Coordinator Infectious Diseases PGY2 Infectious Diseases Residency Program Director Disclosures Consultant
More informationAntibiotic courses and antibiotic conservation, getting the balance right
Antibiotic courses and antibiotic conservation, getting the balance right Prof Martin Llewelyn Brighton and Sussex Medical School Brighton and Sussex University Hospitals NHS Trust The King's Fund: Ideas
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationEnglish Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Berit Muller-Pebody HCAI & AMR Department, Centre for Infectious Disease Surveillance and Control Chief Medical Officer
More informationEVALUATION OF A PEDIATRIC ANTIMICROBIAL STEWARDSHIP PROGRAM IN A TERTIARY CARE MEDICAL CENTER
EVALUATION OF A PEDIATRIC ANTIMICROBIAL STEWARDSHIP PROGRAM IN A TERTIARY CARE MEDICAL CENTER By Chou-Cheng Lai A dissertation submitted to Johns Hopkins University in conformity with the requirements
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationHot Topics in Antimicrobial Stewardship. Meghan Brett, MD Medical Director, Antimicrobial Stewardship University of New Mexico Hospital
Hot Topics in Antimicrobial Stewardship Meghan Brett, MD Medical Director, Antimicrobial Stewardship University of New Mexico Hospital Antimicrobial Stewardship Goals Primary Goal Optimize clinical outcomes
More informationImpact of Antimicrobial Stewardship Program
Impact of Antimicrobial Stewardship Program Ripal Joshi, Pharm.D. AAHIVP Tampa General Hospital January 28, 2016 Objectives Provide an overview on antimicrobial stewardship programs (ASP) Describe the
More informationAntimicrobial Drug Prescriptions in Ambulatory Care Settings, United States, Linda F. McCaig,* Richard E. Besser,* and James M.
Antimicrobial Drug Prescriptions in Ambulatory Care Settings, United States, 1992 2000 Linda F. McCaig,* Richard E. Besser,* and James M. Hughes* During the 1990s, as antimicrobial resistance increased
More informationHealthcare Facilities and Healthcare Professionals. Public
Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:
More informationLinda Taggart MD FRCPC Infectious Diseases Physician Lead Physician, Antimicrobial Stewardship Program St. Michael s Hospital
Linda Taggart MD FRCPC Infectious Diseases Physician Lead Physician, Antimicrobial Stewardship Program St. Michael s Hospital no industry conflicts of interest salary support to lead Antimicrobial Stewardship
More informationOutpatient Antibiotic Use and Stewardship in Minnesota. Catherine Lexau, PhD, MPH, RN Epidemiologist Principal Emma Leof, MPH CSTE Fellow May 1, 2018
Outpatient Antibiotic Use and Stewardship in Minnesota Catherine Lexau, PhD, MPH, RN Epidemiologist Principal Emma Leof, MPH CSTE Fellow May 1, 2018 Agenda Outpatient Antibiotic Use Summary Measuring Antibiotic
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationUpdates in Antimicrobial Stewardship
Updates in Antimicrobial Stewardship Andrew Hunter, Pharm.D., BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center andrew.hunter@va.gov Disclosures No disclosures
More informationThe Big Picture: Using Antibiotic Use and Surveillance Data to Better Inform Stewardship in Healthcare Settings
The Big Picture: Using Antibiotic Use and Surveillance Data to Better Inform Stewardship in Healthcare Settings Becky Roberts, MS Get Smart: Know When Antibiotics Work Office of Antibiotic Stewardship
More information